



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Carotuximab

Cat. No.:	HY-P99494
CAS No.:	1268714-50-6
Target:	TGF-beta/Smad
Pathway:	Stem Cell/Wnt; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions ^{[1][2]} .									
In Vitro	<p>Carotuximab (TRC105; 300 µg/mL; pretreatment 1 h, and then co-cultured for 12 h) reduces the 7-Ketocholesterol-induced endoglin (Eng) protein levels and pSmad1/5 and pSmad2/3 signaling in human aortic endothelial cells (HAoECs). Carotuximab mediated blockage of Eng prevented 7-Ketocholesterol-induced adhesion and transmigration of monocytes through endothelial monolayers^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human aortic endothelial cells (HAoECs)</td> </tr> <tr> <td>Concentration:</td> <td>300 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>Pretreatment 1 h, and then co-cultured for 12 h</td> </tr> <tr> <td>Result:</td> <td>Reduced the 7-Ketocholesterol-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling.</td> </tr> </table>		Cell Line:	Human aortic endothelial cells (HAoECs)	Concentration:	300 µg/mL	Incubation Time:	Pretreatment 1 h, and then co-cultured for 12 h	Result:	Reduced the 7-Ketocholesterol-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling.
Cell Line:	Human aortic endothelial cells (HAoECs)									
Concentration:	300 µg/mL									
Incubation Time:	Pretreatment 1 h, and then co-cultured for 12 h									
Result:	Reduced the 7-Ketocholesterol-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling.									
In Vivo	<p>Carotuximab (TRC105; 2 mg/kg; i.v; every 3 days; for 8 weeks) along with Decitabine results in a more durable anti-leukemic effect in acute myeloid leukemia (AML) xenografts. And also enhances reactive oxygen species (ROS) activity^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female NSG (NOD.Cg-Prkdc^{scid} Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells^[2]</td> </tr> <tr> <td>Dosage:</td> <td>2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v; every 3 days; for 8 weeks</td> </tr> <tr> <td>Result:</td> <td>Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts.</td> </tr> </table>		Animal Model:	Female NSG (NOD.Cg-Prkdc ^{scid} Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells ^[2]	Dosage:	2 mg/kg	Administration:	i.v; every 3 days; for 8 weeks	Result:	Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts.
Animal Model:	Female NSG (NOD.Cg-Prkdc ^{scid} Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells ^[2]									
Dosage:	2 mg/kg									
Administration:	i.v; every 3 days; for 8 weeks									
Result:	Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts.									

REFERENCES

- [1]. Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. *Front Med (Lausanne)*. 2022 Sep 7;9:845918.
- [2]. June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. *Heliyon*. 2020 Oct 13;6(10):e05242.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA